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Introduction {#s1}
============

Traditional tests to evaluate chemicals for their potential impact on human and environmental health are performed using animal models, with varying degrees of success in accurately identifying hazards. Advances in science and technology offer the potential to develop more effective approaches based on combining higher-throughput testing methods, human cell--based systems, small model organisms, and computational models. Development and acceptance of new approaches that reduce and replace animal use for better predictivity of human health outcomes require that regulators, test method developers, and computational modelers have access to high-quality toxicity data. Ideally, these data and relevant analysis tools would be available in a user-friendly format that facilitates data integration and exploration, encourages hypothesis generation, and allows for computational processing and modeling. In reality, progress in developing and evaluating new approaches is often hindered by the lack of open-source central access points for curated data on which models can be built or tested. In addition, the data available are often of unknown quality; constructing models or validating new methodologies on such data produces models and test systems with high uncertainty and suboptimal performance. Ultimately, locating and accessing the types of data needed---data in a structured format with metadata or annotation sufficient to gauge their quality and applicability---becomes a huge time sink for researchers and a barrier to innovation.

Existing sources of toxicity test data have advantages and limitations. The European Chemical Agency's registered substances list ([@c2]) contains detailed information and test results on thousands of substances obtained from chemical dossiers submitted by manufacturers. Although this resource has depth of information, the data contained in it do not fully support computational analysis owing to the database's restrictions on data use, to its limited batch query capability, and to formatting variations of the data fields. The U.S. Environmental Protection Agency (EPA) has several web-based resources providing information on chemical properties and toxicity data available in a computational-friendly format without restrictions on use. These include ToxCast™ data available through the tcpl package ([@c3]), Aggregated Computational Toxicology Resource (ACToR) ([@c5], [@c6]), and the Chemistry Dashboard ([@c15]). These U.S. EPA resources are extremely valuable because they provide detailed information on chemical properties and activities from various sources. However, building and evaluating new approaches require different types of data to be combined in a structured format that is informed by relevant biology or toxicity end points. This task is best facilitated by having the data organized by test guidelines or regulatory end points, a feature that is not currently provided by any of these U.S. EPA resources. Similar challenges with respect to organization exist with other resources such as PubChem ([@c8]; [@c16]) and the Toxicological Data Network from the U.S. National Library of Medicine ([@c11]), as well as the Chemical Effects in Biological Systems (CEBS) database from the National Institute of Environmental Health Sciences (NIEHS) ([@c10]), all of which provide rich content but may not meet data structure needs.

The National Toxicology Program's Integrated Chemical Environment (ICE) is a web-based resource (<https://ice.ntp.niehs.nih.gov>) that provides access to curated data and tools that can be used in the development, validation, and implementation of *in vitro* and *in silico* approaches that reduce and replace the use of animals in toxicity testing. The ICE data integrator function allows users to query high-quality *in vivo* and *in vitro* test results by chemical and by end point. ICE also includes reference chemical lists and supporting data sets, as well as computational predictions for properties such as physicochemical parameters and clearance rates, which are often needed in model development.

ICE Overview {#s2}
============

The current release of ICE features *in vivo* and *in vitro* data sets covering regulatory test end points such as acute oral and dermal toxicity, skin irritation and sensitization, eye corrosion, and endocrine disruption as well as *in silico* predictions of test end points and chemical properties ([Table 1](#t1){ref-type="table"}). These data sets include data assembled and curated by the National Toxicology Program Interagency Center for Evaluation of Alternative Toxicological Methods (NICEATM) during past evaluations of new test methods and reference chemical lists generated from these efforts. ICE also includes a curated version of the high-throughput screening (HTS) data from Tox21^TM^ and ToxCast™ ([@c4]; [@c7]; [@c12]; [@c13]), with data filtered on the basis of chemical quality control information from the National Center for Advancing Translational Sciences and flags generated by the U.S. EPA's tcpl pipeline ([@c3]; [@c14];). Additional data sets will be added with future releases.

###### 

Data types included in 2017 ICE releases and example end points.

Table 1 The table lists data types in the first column and the corresponding availability, type (in vitro or in vivo), and endpoint examples in the remaining columns.

  Data types                             Availability               Type                                            End point examples
  -------------------------------------- -------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------
  Acute dermal toxicity                  October 2017 (tentative)   *In vivo*                                       Rodent LD~50~
  Acute inhalation toxicity              October 2017 (tentative)   *In vivo*                                       Rodent LC~50~
  Acute oral toxicity                    March 2017                 *In vivo*                                       Rodent LD~50~
  Acute oral toxicity                    March 2017                 *In vitro*[^*a*^](#t1n1){ref-type="table-fn"}   Basal cytotoxicity IC~50~
  Androgenic activity                    March 2017                 *In vitro*                                      Androgen receptor binding and transactivation (agonist and antagonist activity)
  Androgenic activity                    July 2017 (tentative)      *In vivo*                                       Lowest effect level in the rodent Hershberger assay
  Androgenic activity                    March 2017                 *In silico*                                     Androgen receptor pathway model scores
  Curated HTS                            March 2017                 *In vitro*                                      Assay ACC, AC~50~
  Dermal irritation                      March 2017                 *In vivo*                                       Skin irritation/corrosion classification categories
  Dermal sensitization                   March 2017                 *In vivo*                                       Mouse LLNA EC~3~ and human patch test lowest effect level
  Dermal sensitization                   March 2017                 *In vitro*                                      KeratinoSens™, DPRA, hCLAT assay results
  Dermal sensitization                   July 2017 (tentative)      *In silico*                                     Binary sensitizer/nonsensitizer call
  Estrogenic activity                    March 2017                 *In vivo*                                       Lowest effect level in the rodent uterotrophic assay
  Estrogenic activity                    March 2017                 *In silico*                                     Estrogen receptor pathway model scores
  Ocular irritation                      March 2017                 *In vivo*                                       Eye irritation/corrosion classification categories
  Physicochemical property predictions   March 2017                 *In silico*                                     LogP, logVP, logBCF, logS, melting point, boiling point

Notes: AC50, concentration that increases activity by 50%; ACC, activity concentration at cutoff, a measure of the activity threshold for an assay response based on curve-fitting models; EC3, in the LLNA, a test chemical concentration that produces a stimulation index of 3; hCLAT, human cell line activation test; IC50, concentration that inhibits activity (in this context, decreases cell viability) by 50%; LC50, inhalation concentration expected to produce lethality in 50% of animals tested; LD50, dose expected to produce lethality in 50% of animals tested; LLNA, local lymph node assay; physicochemical properties characterized as log values are log 10; logBCF, log of the bioconcentration factor; logP, octanol-water partition coefficient; logVP, the vapor pressure; logS, log of the solubility in water.

*In vitro* data were used to develop a nonanimal method for setting starting doses for *in vivo* acute oral toxicity studies.

The query function of ICE, the integrator, facilitates combining the different data sets within ICE, allowing users to merge data points from the different data sets to simultaneously examine end points based on all available substance data or by using an input list of chemicals. Upon submission of the query, the user is provided with an overview of the query results along with several exportable data views, supporting both computational manipulation and manual interaction.

To assist the user with developing and interpreting queries, ICE provides a "Help" page that walks the user through building a search and understanding search output. Other user support resources include a "Home" page where updates and other news will be announced, an "About" page with background information, and a "Data Sets" page with information about the sources of the data in ICE. This page includes links that lead to more detailed information about each data set, including references and metadata for context about the data end points. Some information about the studies available in the source data sets is not available in ICE (for example, detailed clinical observations or some study protocol details), but it is available via the provided links and will also be accessible via CEBS ([@c10]) to facilitate integration with other data resources from the NIEHS.

User Stories {#s3}
============

We developed ICE to address needs that have been expressed frequently by NICEATM stakeholders. As such, we tailored the design of ICE around user stories that developed from those needs. Here, we describe stories from three different user groups (method developer, chemical producer, risk assessor) and how ICE can help meet these users' needs ([Figure 1](#f1){ref-type="fig"}).

![Integrated Chemical Environment (ICE) users, resources, and outcomes. ICE was developed to support three main user roles: method developers, chemical producers, and risk assessors. The center panel lists the resources ICE provides to help these user groups complete some of the major tasks listed in the right panel.](EHP1759_f1){#f1}

Method Developer {#s4}
================

Method developers are developing new *in vitro* or *in silico* methods to prioritize substances for further toxicity testing, or to test a substance for potential health impacts. The availability of data anchored to regulatory end points of interest from ICE facilitates exploration of the current state of methods, and such curated end point data can be compared with user-generated test data. These capabilities help method developers improve the performance of existing methods or target new method development to areas where the currently available test methods leave room for improvement. Furthermore, by having *in vivo* data organized with the *in vitro* and *in silico* data, it is easier to identify data gaps that may be targeted using *in silico* approaches.

*In vitro* test method developers often need reference chemicals, which are chemicals that cause specific, well-characterized biological effects and can therefore be used to assess the performance of a test method designed to measure that effect. These reference chemicals, along with the supporting data, are helpful in both *in vitro* method development and validation efforts. The reference chemical lists included in ICE provide a starting place to identify test materials and associated data.

For those developing *in silico* approaches, good quality data are important for training and testing predictive models. Method developers will find that the data in ICE are well annotated, cleaned, and formatted to support *in silico* modeling, allowing them to focus on method optimization versus data preparation. ICE currently provides many of the parameters needed as input for these models, and open-source workflows for *in vitro* to *in vivo* extrapolation and chemical property prediction will be added to ICE later in 2017.

Chemical Producer {#s5}
=================

For developers of new products for which toxicity testing will be required, typical testing needs include prioritizing substances to move forward through the development process and generating data needed to meet regulatory requirements. The ICE integrator allows the chemical producer to input a list of chemicals and obtain available testing data, which may help with evaluating the potential for adverse impacts during lead agent prioritization.

For chemical producers seeking to replace animals required for testing, the ICE integrator allows end point--oriented searches to compare data sets across all available substances. This capability allows the chemical producer to compare the results coming from different test methods relating to a specific end point. A query that returns *in vitro* and *in silico* test results paired with *in vivo* animal data may allow the chemical producer to better identify which nonanimal methods will best meet their information needs. This information may provide the chemical producer with the confidence in those nonanimal methods that is needed to change in-house testing approaches for ones that use fewer animals, save money, and better predict the end point of interest.

Risk Assessor {#s6}
=============

Similar to the chemical producer, the risk assessor may want to obtain available animal or human test data on a list of chemicals or review available data from nonanimal methods. Resources currently in ICE can help risk assessors with prioritizing chemicals for further toxicity testing and with identifying the most informative tests for that purpose in addition to providing data on the likely health impacts of a substance. The ICE data explorer view provides user-friendly data interaction and an easy-to-use snapshot of the types of data and end points. This information can be useful in prioritization or in identification of data gaps. The risk assessor may also be interested in comparing the performance of nonanimal test data with existing guideline animal test results across a wide range of chemicals, which is easily done using the ICE integrator.

ICE supports the exporting of data, which facilitates more detailed comparisons of end point variability. Exported data are preformatted and ready for analysis, enabling the risk assessor to move easily from query output into the subsequent analysis workflows. Transparency and reproducibility of data and process are important to the risk assessor; therefore, ICE provides reference details on the Data Sets page and clear referencing from the query output.

Next Steps {#s7}
==========

Computational tools will be included in ICE by the fall of 2017. These programs and workflows developed by NICEATM staff and external partners will enable researchers to conduct analyses locally using either their own data or data downloaded from ICE. Currently in the development queue are machine learning models for six physicochemical properties ([@c18]), predictive signatures based on HTS data such as embryonic vascular disruption leading to adverse prenatal outcomes ([@c9]), and *in vivo*--to--*in vitro* extrapolation (IVIVE) workflows ([@c1]; [@c17]). In addition to downloadable predictions and workflows, interactive tools such as those that facilitate biological pathway--informed IVIVE are needed to help link *in vitro* activity concentrations to relevant *in vivo* exposures and outcomes.

Future versions of ICE will also include tutorials aimed at helping users better understand the tools available in ICE and their applications in regulatory safety testing. These tutorials will address questions that frequently arise about appropriate use of computational tools and models on topics such as characterizing the domain of applicability and model uncertainty. Development of these resources is currently underway with a tentative 2018 launch date.
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